Efficacy and safety of fluzoparib combined with anlotinib in extensive stage small cell lung cancer after first-line platinum-based chemotherapy: a multi-center, single-arm prospective phase II clinical study (STAMP study)

BACKGROUND: Small-cell lung cancer (SCLC) is a highly aggressive and lethal malignancy that accounts for 10–15% of lung cancers, and it is generally divided into limited and extensive stage. The standard of care for patients with newly diagnosed extensive-stage SCLC (ES-SCLC) is still platinum-based...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Deyu, Huang, Zhangzhou, Zhong, Jiangming, Lin, Li, Zhang, Guifeng, Zhuang, Wu, Liu, Zhenhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10424452/
https://www.ncbi.nlm.nih.gov/pubmed/37580661
http://dx.doi.org/10.1186/s12885-023-11230-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10424452/
https://www.ncbi.nlm.nih.gov/pubmed/37580661
http://dx.doi.org/10.1186/s12885-023-11230-5

Ejemplares similares